Valeant Pharmaceuticals International (NYSE: VRX) reported that its pain medication for shingles patients failed a mid-stage clinical study sending the stock price plummeting $2.32 to close at $24.85.
Valeant's Pain Medication Fails Study
August 24, 2009 at 17:52 PM EDT
